ABEO stock

Is Abeona Therapeutics Inc (ABEO) undervalued? · rev $3.5M

Abeona Therapeutics Inc (ABEO) is a biotechnology company listed on US.

This page asks whether Abeona Therapeutics Inc (ABEO) looks cheap on cached numbers — not a DCF toy and not a buy alert.

Latest reported ABEO revenue for 2023-12-31 was $3.5M. Net income was -$54.2M. Revenue was up 147.5% from 2022-12-31 to 2023-12-31. ABEO currently screens at market cap $301.8M.

ABEO currently screens at market cap $301.8M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.

A new ABEO 10-Q can flip this screen overnight. The SEC page is the source.

Not investment advice. Compare ABEO to the stock page model before you treat a low multiple as a gift.

Not investment advice.

Full ABEO analysis